p53 Gene Mutation and Chemotherapy Resistance in Astrocytic Tumors
Author Information
Author(s): Y Iwadate, M Tagawa, S Fujimoto, M Hirose, H Namba, K Sueyoshi, S Sakiyama, A Yamaura
Primary Institution: Chiba University and Chiba Cancer Center
Hypothesis
The status of the p53 gene in astrocytic tumors influences their resistance to chemotherapy.
Conclusion
Mutated p53 genes in astrocytic tumors are associated with increased resistance to DNA-damaging agents but not to anti-microtubule agents.
Supporting Evidence
- The study found that 41% of the tumor samples had mutations in the p53 gene.
- Mutated p53 tumors showed a significantly lower percentage of effective agents compared to wild-type tumors.
- All DNA-damaging agents tested were less effective in p53-mutated cases.
Takeaway
If a tumor has a broken p53 gene, it might not respond well to certain cancer treatments that damage DNA, but it could still be treated with other types of drugs.
Methodology
The study examined 56 astrocytic tumor specimens for p53 mutations and their sensitivity to 30 different anti-cancer agents using flow cytometry.
Limitations
The study's findings may be influenced by the heterogeneity of clinical cases.
Participant Demographics
Included 56 patients with astrocytic tumors, categorized into grade II, III, and IV.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website